2024-04-01 20:58:00 ET
Summary
- Bristol-Myers Squibb has expected 2024 annual revenue of $45.85B and expected annual earnings per share of $6.83.
- BMY is currently below its 10-month exponential moving average (EMA), indicating bearish price action.
- However, there are signs of institutional accumulation, short-term bullish momentum, and potential improvement in relative strength.
Bristol-Myers Squibb, Inc. ( BMY ) is in the health care sector and in the pharmaceutical industry. While not a factor in my analysis of the company, BMY is expected to have 2024 annual revenue of $45.85B and annual earnings per share of $6.83. BMY is also yielding a safe 4.43%. In this article I will outline why I think BMY is a speculative buy at this price. It is speculative because not all of my preferred parameters are in place yet as I will outline in the article. My investment thesis will be formed by analyzing the price action, momentum, volume, and relative strength of BMY in two different time frames....
Read the full article on Seeking Alpha
For further details see:
Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)